| emotional neglect |
phenotype |
3 |
1 |
emotional neglect |
| emotional reactivity |
phenotype |
4 |
2 |
emotional reactivity |
| emotional stability |
phenotype |
2 |
1 |
|
| emotion regulation |
phenotype |
16 |
13 |
capacity for emotion regulation, difficulty expressing emotions, effective emotion regulation, emotion regulation deficits, emotion-regulation deficits, poor emotional regulation |
| empathy |
phenotype |
3 |
1 |
|
| employed |
phenotype |
4 |
3 |
freelancers, full-time, part-time |
| employment |
phenotype |
18 |
9 |
currently employed or not, employment, employment status |
| EMT |
phenotype |
5 |
1 |
EMT phenotype, epithelial-mesenchymal transition |
| ENCODE project |
cohort |
18 |
6 |
ENCODE, ENCODE project |
| endocannabinoids |
drug |
12 |
8 |
EC, eCB, eCBs, endogenous ligands at CB receptors, exogenous cannabinoids |
| endocannabinoid system |
drug |
11 |
11 |
eCB, eCB system, endocannabinoid signaling, endocannabinoid system, endocannabinoids |
| endogenous opioids |
drug |
11 |
10 |
endogenous opioid peptides, endogenous opioids, opioids |
| endophenotype |
phenotype |
18 |
13 |
EEG, characteristic traits, cognitive endophenotypes, component phenotype, endophenotype, endophenotypes, intermediate phenotype, intermediate phenotypes, subphenotype |
| endorphin |
drug |
4 |
2 |
endogenous MOR ligand |
| energy expenditure |
phenotype |
3 |
3 |
EE |
| energy homeostasis |
phenotype |
8 |
7 |
metabolic balance |
| England |
cohort |
2 |
— |
England population, England survey |
| enhancer |
drug |
9 |
3 |
active enhancer |
| ENIGMA |
cohort |
8 |
4 |
ENIGMA consortium, ENIGMA imputation protocols |
| ENIGMA consortium |
cohort |
4 |
— |
ENIGMA |
